^
    Back
    Association details:
    Biomarker:FGF21 elevation
    Cancer:Hepatocellular Cancer
    Drug:Lenvima (lenvatinib) (c-KIT inhibitor, FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PDGFR α antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Clin Cancer Res
    Title:

    Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase 3 REFLECT Study

    Published date:
    06/09/2021
    Excerpt:
    CONTRADICTING EVIDENCE: 407 patients were included in the serum analysis set (lenvatinib n=279, sorafenib n=128); 58 patients were included in the gene-expression analysis set (lenvatinib n=34, sorafenib n=24)….Higher baseline VEGF, ANG2, and FGF21 correlated with shorter OS in both treatment groups.
    DOI:
    10.1158/1078-0432.CCR-20-4219
    Trial ID:
    REFLECT
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    ESMO 2018
    Title:

    Final analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]

    Published date:
    10/01/2018
    Excerpt:
    ...for pts with high baseline FGF21 (LEN, n = 70; SOR, n = 27), OS was longer for LEN vs SOR (median, 10.9 vs 6.8 months; HR, 0.528; 95% CI, 0.328–0.849; P = 0.0075),…
    DOI:
    https://doi.org/10.1093/annonc/mdy269.057
    Trial ID:
    REFLECT